Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21058416,flow rate,The mobile phase used was acetonitrile and 50 mm ammonium acetate buffer at a flow rate of 1 mL/min.,Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ml] / [min],1,3720,DB01023,Felodipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,5.12,3721,DB01023,Felodipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,10.53,3722,DB01023,Felodipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,7.14,3723,DB01023,Felodipine
,21058416,C(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],394.6,3724,DB01023,Felodipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.6,3725,DB01023,Felodipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],2624.2,3726,DB01023,Felodipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],44.4,3727,DB01023,Felodipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.5,3728,DB01023,Felodipine
,21058416,AUC(0-24),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],275.8,3729,DB01023,Felodipine
,7768080,maximum effect (Emax),The maximum effect (Emax) characterizing dose response was found to increase linearly with age and was estimated to be 20.6 mm Hg in the typical individual (60 years of age).,Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768080/),hg·mm,20.6,5522,DB01023,Felodipine
,7768080,D50),The dose at which 50% of the maximum effect is achieved (D50) was estimated to be 11.1 mg.,Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768080/),mg,11.1,5523,DB01023,Felodipine
,7768080,Emax,The Emax characterizing concentration response also increased linearly with age and was estimated to be 27.8 mm Hg for the typical individual.,Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768080/),hg·mm,27.8,5524,DB01023,Felodipine
,7768080,C50),The concentration at which 50% of the maximum effect is achieved (C50) was related to plasma renin activity (PRA) by the following: (21.6.PRA)/(0.25 + PRA) nmol/L; its value in the typical individual was estimated to be about 16.9 nmol/L.,Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768080/),[nM] / [l],21,5525,DB01023,Felodipine
,7768080,C50),The concentration at which 50% of the maximum effect is achieved (C50) was related to plasma renin activity (PRA) by the following: (21.6.PRA)/(0.25 + PRA) nmol/L; its value in the typical individual was estimated to be about 16.9 nmol/L.,Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768080/),[nM] / [l],16.9,5526,DB01023,Felodipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB01023,Felodipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB01023,Felodipine
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB01023,Felodipine
,3766146,half-lives,Both myocardial accumulation and disposition pharmacokinetics of the drug showed one-compartment characteristics with half-lives of about 97 min.,"Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),min,97,10987,DB01023,Felodipine
,3766146,Apparent Vd,"Apparent Vd was about 480 ml/g myocardial tissue, which expresses a very pronounced binding and accumulation of felodipine in the rabbit myocardium in vitro.","Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),[ml] / [g],480,10988,DB01023,Felodipine
,12235445,inhibition constant [K(i)],"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μg] / [ml],35.9,15936,DB01023,Felodipine
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],87.0,15937,DB01023,Felodipine
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],124.0,15938,DB01023,Felodipine
,12235445,K(i),Ascorbyl palmitate was more potent (K(i) = 12.3 +/- 0.5 micromol/L).,Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],12.3,15939,DB01023,Felodipine
<,33493600,oral bioavailability,"Felodipine is a calcium channel blocker, which shows low oral bioavailability (<15%) owing to poor water solubility and high first pass metabolism.","Oral bioavailability improvement of felodipine using tailored microemulsion: Surface science, ex vivo and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493600/),%,15,21590,DB01023,Felodipine
,33493600,relative bioavailability,"The in vivo pharmacokinetic parameters in the rat model confirmed the improvement in oral bioavailability with microemulsion (relative bioavailability = 21.9) in comparison to the felodipine suspension, due to high surface area of oil droplets and its lymphatic uptake via transcellular route.","Oral bioavailability improvement of felodipine using tailored microemulsion: Surface science, ex vivo and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493600/),,21.9,21591,DB01023,Felodipine
,23303553,total chromatographic run time,"The total chromatographic run time was 4.0 min and the elution of FDP, MPL and IS occurred at 1.05, 2.59 and 1.65 min, respectively.",Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23303553/),min,4.0,25739,DB01023,Felodipine
,2081141,sustained effective plasma concentration,"This was, however, not statistically significant but was related to a sustained effective plasma concentration of the drug (6 nmol/l).",Pharmacokinetics and hemodynamic and diuretic/natriuretic effects of felodipine administered as an extended-release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2081141/),[nM] / [l],6,26094,DB01023,Felodipine
,29714001,relative bioavailability,The relative bioavailability of felodipine from the designed gel was 1.7.,Dry Gel Containing Optimized Felodipine-Loaded Transferosomes: a Promising Transdermal Delivery System to Enhance Drug Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29714001/),,1.7,26701,DB01023,Felodipine
,8562295,AUC,2. Initial grapefruit juice treatment increased felodipine AUC (mean +/- s.d.; 56.6 +/- 21.9 vs 28.1 +/- 11.5 ng ml-1 h; P < 0.001) and Cmax (8.1 +/- 2.5 vs 3.3 +/- 1.2 ng ml-1; P < 0.001) compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[h·ng] / [ml],56.6,27765,DB01023,Felodipine
,8562295,AUC,2. Initial grapefruit juice treatment increased felodipine AUC (mean +/- s.d.; 56.6 +/- 21.9 vs 28.1 +/- 11.5 ng ml-1 h; P < 0.001) and Cmax (8.1 +/- 2.5 vs 3.3 +/- 1.2 ng ml-1; P < 0.001) compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[h·ng] / [ml],28.1,27766,DB01023,Felodipine
,8562295,Cmax,2. Initial grapefruit juice treatment increased felodipine AUC (mean +/- s.d.; 56.6 +/- 21.9 vs 28.1 +/- 11.5 ng ml-1 h; P < 0.001) and Cmax (8.1 +/- 2.5 vs 3.3 +/- 1.2 ng ml-1; P < 0.001) compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[ng] / [ml],8.1,27767,DB01023,Felodipine
,8562295,Cmax,2. Initial grapefruit juice treatment increased felodipine AUC (mean +/- s.d.; 56.6 +/- 21.9 vs 28.1 +/- 11.5 ng ml-1 h; P < 0.001) and Cmax (8.1 +/- 2.5 vs 3.3 +/- 1.2 ng ml-1; P < 0.001) compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[ng] / [ml],3.3,27768,DB01023,Felodipine
,8562295,tmax,Felodipine tmax (median; 2.8 vs 3.0 h) and t1/2 (7.3 +/- 3.7 vs 6.9 +/- 3.6 h) were not altered.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),h,2.8,27769,DB01023,Felodipine
,8562295,tmax,Felodipine tmax (median; 2.8 vs 3.0 h) and t1/2 (7.3 +/- 3.7 vs 6.9 +/- 3.6 h) were not altered.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),h,3.0,27770,DB01023,Felodipine
,8562295,t1/2,Felodipine tmax (median; 2.8 vs 3.0 h) and t1/2 (7.3 +/- 3.7 vs 6.9 +/- 3.6 h) were not altered.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),h,7.3,27771,DB01023,Felodipine
,8562295,t1/2,Felodipine tmax (median; 2.8 vs 3.0 h) and t1/2 (7.3 +/- 3.7 vs 6.9 +/- 3.6 h) were not altered.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),h,6.9,27772,DB01023,Felodipine
,8562295,AUC,3. Readministration of felodipine with grapefruit juice produced mean felodipine AUC (61.5 +/- 32.2 ng ml-1 h) and Cmax (8.4 +/- 4.8 ng ml-1) which were similar to the initial grapefruit juice treatment 1-3 weeks previously.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[h·ng] / [ml],61.5,27773,DB01023,Felodipine
,8562295,Cmax,3. Readministration of felodipine with grapefruit juice produced mean felodipine AUC (61.5 +/- 32.2 ng ml-1 h) and Cmax (8.4 +/- 4.8 ng ml-1) which were similar to the initial grapefruit juice treatment 1-3 weeks previously.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[ng] / [ml],8.4,27774,DB01023,Felodipine
,8562295,AUC,Dehydrofelodipine AUC (74.7 +/- 28.7 vs 48.5 +/- 16.3 ng ml-1 h; P < 0.01) and Cmax (12.1 +/- 2.9 vs 7.9 +/- 2.6 ng ml-1; P < 0.01) were augmented with grapefruit juice compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[h·ng] / [ml],74.7,27775,DB01023,Felodipine
,8562295,AUC,Dehydrofelodipine AUC (74.7 +/- 28.7 vs 48.5 +/- 16.3 ng ml-1 h; P < 0.01) and Cmax (12.1 +/- 2.9 vs 7.9 +/- 2.6 ng ml-1; P < 0.01) were augmented with grapefruit juice compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[h·ng] / [ml],48.5,27776,DB01023,Felodipine
,8562295,Cmax,Dehydrofelodipine AUC (74.7 +/- 28.7 vs 48.5 +/- 16.3 ng ml-1 h; P < 0.01) and Cmax (12.1 +/- 2.9 vs 7.9 +/- 2.6 ng ml-1; P < 0.01) were augmented with grapefruit juice compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[ng] / [ml],12.1,27777,DB01023,Felodipine
,8562295,Cmax,Dehydrofelodipine AUC (74.7 +/- 28.7 vs 48.5 +/- 16.3 ng ml-1 h; P < 0.01) and Cmax (12.1 +/- 2.9 vs 7.9 +/- 2.6 ng ml-1; P < 0.01) were augmented with grapefruit juice compared with water.,Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562295/),[ng] / [ml],7.9,27778,DB01023,Felodipine
,8451779,bioavailability,"This reduction in FEL bioavailability is much smaller than that observed after co-administration of carbamazepine (CBZ) (i.e., 94%).",Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451779/),%,94,49762,DB01023,Felodipine
,22339303,disintegration times,"The in vitro and in vivo disintegration times of FLODT-2 were 9 and 7 s, respectively.","Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: development, optimization and in vitro/in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339303/),s,9,58324,DB01023,Felodipine
,22339303,disintegration times,"The in vitro and in vivo disintegration times of FLODT-2 were 9 and 7 s, respectively.","Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: development, optimization and in vitro/in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339303/),s,7,58325,DB01023,Felodipine
,16685052,area under the curve,"The median and range of the area under the curve and the maximum concentration of felodipine were significantly (P < 0.001) greater with consumption of GFJ [110 (range: 58-270) nmol . h/L and 21 (7.6-50) nmol/L, respectively] than with that of orange juice [54 (29-150) nmol .",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),[h·nM] / [l],110,61482,DB01023,Felodipine
,16685052,maximum concentration,"The median and range of the area under the curve and the maximum concentration of felodipine were significantly (P < 0.001) greater with consumption of GFJ [110 (range: 58-270) nmol . h/L and 21 (7.6-50) nmol/L, respectively] than with that of orange juice [54 (29-150) nmol .",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),[nM] / [l],21,61483,DB01023,Felodipine
,16685052,maximum concentration,"The median and range of the area under the curve and the maximum concentration of felodipine were significantly (P < 0.001) greater with consumption of GFJ [110 (range: 58-270) nmol . h/L and 21 (7.6-50) nmol/L, respectively] than with that of orange juice [54 (29-150) nmol .",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),nM,54,61484,DB01023,Felodipine
,16685052,time to reach maximum plasma concentration,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,2.5,61485,DB01023,Felodipine
,16685052,time to reach maximum plasma concentration,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,2.8,61486,DB01023,Felodipine
,16685052,time to reach maximum plasma concentration,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,2.5,61487,DB01023,Felodipine
,16685052,terminal half-life,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,6.6,61488,DB01023,Felodipine
,16685052,terminal half-life,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,7.8,61489,DB01023,Felodipine
,16685052,terminal half-life,"GFJ, orange juice, and furanocoumarin-free GFJ did not differ significantly (P > 0.09) in median time to reach maximum plasma concentration [2.5 (1.5-6), 2.8 (1.5-4), and 2.5 (2-6) h, respectively] or terminal half-life [6.6 (4.2-13.6), 7.8 (4.4-13.2), and 6.8 (2.6-14.4) h, respectively].",A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16685052/),h,6.8,61490,DB01023,Felodipine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"2,260",77923,DB01023,Felodipine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"1,730",77924,DB01023,Felodipine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"5,200",77925,DB01023,Felodipine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"4,390",77926,DB01023,Felodipine
,2153819,IC50,"One of the compounds, 2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6- methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]acetamide (26, UK-51,656), was identified as a potent (IC50 = 4 x 10(-9) M) calcium antagonist which is 20-fold selective for vascular over cardiac tissue and which has a markedly longer duration of action (greater than 5 h) than nifedipine in the anesthetized dog on intravenous administration.","Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),M,4 x 10(-9),78543,DB01023,Felodipine
,2153819,half-life,The pharmacokinetic half-life of 26 was established as 4.7 h and possible explanations are advanced to account for 26 having a shorter plasma half-life than amlodipine and a longer plasma half-life than felodipine.,"Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),h,4.7,78544,DB01023,Felodipine
,21950148,"t(max,ss","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),h,3.32,78861,DB01023,Felodipine
,21950148,"CG(max,ss)","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[nM] / [l],13.12,78862,DB01023,Felodipine
,21950148,AUG(tau),"The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[h·nM] / [l],136.33,78863,DB01023,Felodipine
,3987557,volume of distribution,The major fraction of the felodipine dose is localised extravascularly with a volume of distribution of about 10 L/kg.,"Absorption, distribution and elimination of felodipine in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987557/),[l] / [kg],10,79749,DB01023,Felodipine
greater,3987557,elimination half-life,The mean elimination half-life of felodipine is greater than 10 hours.,"Absorption, distribution and elimination of felodipine in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987557/),h,10,79750,DB01023,Felodipine
,10606837,turnover rate,"The model gave a turnover rate of CYP3A4 of 0.0849 h-1, corresponding to a half-life of 8.16 h, in agreement with reported values.",Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606837/),1/[h],0.0849,79897,DB01023,Felodipine
,10606837,half-life,"The model gave a turnover rate of CYP3A4 of 0.0849 h-1, corresponding to a half-life of 8.16 h, in agreement with reported values.",Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606837/),h,8.16,79898,DB01023,Felodipine
,25126525,zeta potential,Spherical nanovesicles of 75.71 ± 5.4 nm with PDI 0.228 and zeta potential of -49.8 were adjudged as the best formulation (MF8).,"Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25126525/),,49.8,94462,DB01023,Felodipine
,25126525,deformability index,MF8 displayed maximum entrapment and loading efficiency with a high deformability index of 119.68.,"Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25126525/),,119.68,94463,DB01023,Felodipine
,25126525,flux,In vitro permeation across rat skin by MF8 reported 256% enhancement in permeation (flux = 23.72 ± 0.64) when compared with transdermal control formulation and followed zero order kinetics (Case-II).,"Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25126525/),,23.72,94464,DB01023,Felodipine
,25126525,relative bioavailability,The relative bioavailability of felodipine was found 358.42% versus oral administration that was well supported by the outcomes of confocal laser scanning microscopic studies that suggested rapid permeation of drugs to across dermal layers.,"Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25126525/),%,358.42,94465,DB01023,Felodipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB01023,Felodipine
,27173987,IC50,"In vitro investigation of 8-arm-poly(ethylene glycol) against CYP3A4-catalyzed felodipine metabolism employing human liver microsomes compared closely with naringenin, a typical grapefruit flavonoid, yielding IC50 values of 7.22 and 121.97 μM, respectively.","Enhancement of the Oral Bioavailability of Felodipine Employing 8-Arm-Poly(Ethylene Glycol): In Vivo, In Vitro and In Silico Evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27173987/),μM,7.22,96585,DB01023,Felodipine
,27173987,IC50,"In vitro investigation of 8-arm-poly(ethylene glycol) against CYP3A4-catalyzed felodipine metabolism employing human liver microsomes compared closely with naringenin, a typical grapefruit flavonoid, yielding IC50 values of 7.22 and 121.97 μM, respectively.","Enhancement of the Oral Bioavailability of Felodipine Employing 8-Arm-Poly(Ethylene Glycol): In Vivo, In Vitro and In Silico Evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27173987/),μM,121.97,96586,DB01023,Felodipine
,24898424,AUC ratio,"According to the developed method, the AUC ratio of felodipine was 2.50 and its coefficient of variation (CV) was 45%, which agreed well with the observed AUC ratio of 2.48 and CV of 51%.",Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24898424/),,2.50,100635,DB01023,Felodipine
,24898424,AUC ratio,"According to the developed method, the AUC ratio of felodipine was 2.50 and its coefficient of variation (CV) was 45%, which agreed well with the observed AUC ratio of 2.48 and CV of 51%.",Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24898424/),,2.48,100636,DB01023,Felodipine
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105879,DB01023,Felodipine
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1084.81,105880,DB01023,Felodipine
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105881,DB01023,Felodipine
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1265.0,105882,DB01023,Felodipine
,30243471,flow rate,An isocratic elution of samples was performed on capcell pak C8 DD S5 column (4.6mm×250mm particle size 5μm) column with mobile phase consisting 5mM Phosphate Buffer (pH 4.8 adjusted with dilute ortho-phosphoric acid solution): acetonitrile (25:75:v/v) delivered at flow rate 1.0mLmin-1.,Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[mlmin],1.0,110394,DB01023,Felodipine
,30243471,LODs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.055,110395,DB01023,Felodipine
,30243471,LOQs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.201,110396,DB01023,Felodipine
,25194342,flow rate,"Chromatographic separation was performed on a XB C18 column (2.1mm×50mm, 3.5μm) under isocratic conditions with the mobile phase consisting of acetonitrile and 20mM ammonium acetate buffer (pH 7.0) (40:60, v/v) at the flow rate of 0.3ml/min.",Simultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25194342/),[ml] / [min],0.3,113786,DB01023,Felodipine
,25194342,run time,The run time was 5.5min.,Simultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25194342/),min,5.5,113787,DB01023,Felodipine
,25194342,m,"Mass spectrometric analysis was performed on a triple quadrupole mass spectrometer operated in the multiple reaction monitoring (MRM) mode with the transitions of m/z 473.0→338.2 for clevidipine, m/z 356.1→324.0 for H152/81 and m/z 383.9→338.2 for the IS.",Simultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25194342/),,473.0,113788,DB01023,Felodipine
,25194342,m/,"Mass spectrometric analysis was performed on a triple quadrupole mass spectrometer operated in the multiple reaction monitoring (MRM) mode with the transitions of m/z 473.0→338.2 for clevidipine, m/z 356.1→324.0 for H152/81 and m/z 383.9→338.2 for the IS.",Simultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25194342/),,356.1,113789,DB01023,Felodipine
,3396260,Cmax,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [l],17,113908,DB01023,Felodipine
,3396260,Cmin,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [l],5,113909,DB01023,Felodipine
,3396260,AUC,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [h·l],82,113910,DB01023,Felodipine
,3396260,Systemic availability,Systemic availability was about 15% in both groups.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),%,15,113911,DB01023,Felodipine
,3396260,Plasma clearance (CL),Plasma clearance (CL) was reduced from 56.1 L/h in the young to 25.4 L/h in the elderly.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[l] / [h],56.1,113912,DB01023,Felodipine
,3396260,Plasma clearance (CL),Plasma clearance (CL) was reduced from 56.1 L/h in the young to 25.4 L/h in the elderly.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[l] / [h],25.4,113913,DB01023,Felodipine
,8513655,ratios for AUC,"Dehydrofelodipine/felodipine ratios for AUC (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) and felodipine Cmax (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) were reduced, consistent with inhibition of presystemic felodipine metabolism.","Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513655/),,1.5,116466,DB01023,Felodipine
,8513655,ratios for AUC,"Dehydrofelodipine/felodipine ratios for AUC (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) and felodipine Cmax (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) were reduced, consistent with inhibition of presystemic felodipine metabolism.","Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513655/),,2.2,116467,DB01023,Felodipine
,8513655,Cmax,"Dehydrofelodipine/felodipine ratios for AUC (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) and felodipine Cmax (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) were reduced, consistent with inhibition of presystemic felodipine metabolism.","Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513655/),,1.5,116468,DB01023,Felodipine
,8513655,Cmax,"Dehydrofelodipine/felodipine ratios for AUC (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) and felodipine Cmax (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) were reduced, consistent with inhibition of presystemic felodipine metabolism.","Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513655/),,2.2,116469,DB01023,Felodipine
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],22.8,118072,DB01023,Felodipine
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],49.5,118073,DB01023,Felodipine
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1134.4,118074,DB01023,Felodipine
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1704.7,118075,DB01023,Felodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.8,118076,DB01023,Felodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,7.6,118077,DB01023,Felodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.7,118078,DB01023,Felodipine
,21351826,peak detachment force,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),n,3.12,120907,DB01023,Felodipine
,21351826,work of adhesion,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),mj,0.72,120908,DB01023,Felodipine
,21351826,flux,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),[h·mg] / [cm(2],0.118,120909,DB01023,Felodipine
,21351826,flux,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),[h·mg] / [cm(2],0.331,120910,DB01023,Felodipine
,28480807,P:D ratio,"The optimized formulation was found to be the already prepared formulation T12 (P:D ratio of 40 and 66.67% F127) with suitable T% and EE% of 95.12% and 91.75%, respectively.","Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28480807/),%,40,125338,DB01023,Felodipine
,28480807,P:D ratio,"The optimized formulation was found to be the already prepared formulation T12 (P:D ratio of 40 and 66.67% F127) with suitable T% and EE% of 95.12% and 91.75%, respectively.","Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28480807/),%,66.67,125339,DB01023,Felodipine
,28480807,T%,"The optimized formulation was found to be the already prepared formulation T12 (P:D ratio of 40 and 66.67% F127) with suitable T% and EE% of 95.12% and 91.75%, respectively.","Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28480807/),%,95.,125340,DB01023,Felodipine
,28480807,EE%,"The optimized formulation was found to be the already prepared formulation T12 (P:D ratio of 40 and 66.67% F127) with suitable T% and EE% of 95.12% and 91.75%, respectively.","Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28480807/),%,91.,125341,DB01023,Felodipine
,1880229,Blood,"Blood and dialysate flows were 200 mL/min and 500 mL/min, respectively.",Pharmacokinetics of felodipine in chronic hemodialysis patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),[ml] / [min],200,128210,DB01023,Felodipine
,1880229,dial,"Blood and dialysate flows were 200 mL/min and 500 mL/min, respectively.",Pharmacokinetics of felodipine in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),[ml] / [min],200,128211,DB01023,Felodipine
,1880229,dial,"Blood and dialysate flows were 200 mL/min and 500 mL/min, respectively.",Pharmacokinetics of felodipine in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),[ml] / [min],500,128212,DB01023,Felodipine
,1880229,flows,"Blood and dialysate flows were 200 mL/min and 500 mL/min, respectively.",Pharmacokinetics of felodipine in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),[ml] / [min],500,128213,DB01023,Felodipine
,1880229,clearance,"Dialyzer clearance of radioactive metabolites was about 10 mL/min, and only 8.9% of the dose was eliminated by the treatment.",Pharmacokinetics of felodipine in chronic hemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),[ml] / [min],10,128214,DB01023,Felodipine
,1880229,half-life,The half-life of radioactive metabolites was 10 days (6-14 days) in three patients dialyzed thrice weekly.,Pharmacokinetics of felodipine in chronic hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880229/),d,10,128215,DB01023,Felodipine
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,75,130062,DB01023,Felodipine
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,79,130063,DB01023,Felodipine
,11151741,trough-to-peak ratios (T:P),"The trough-to-peak ratios (T:P) were 75% and 79% for the systolic BP and 70% and 70% for the diastolic BP for the free and fixed combinations, respectively.",The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151741/),%,70,130064,DB01023,Felodipine
,18300480,relative bioavailability,The relative bioavailability of felodipine and metoprolol were 275.37% and 189.76% versus oral administration respectively.,[Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300480/),%,275.37,134124,DB01023,Felodipine
,18300480,relative bioavailability,The relative bioavailability of felodipine and metoprolol were 275.37% and 189.76% versus oral administration respectively.,[Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300480/),%,189.76,134125,DB01023,Felodipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB01023,Felodipine
,8156973,half-life,MHD is eliminated with a half-life of about 8-10 h.,Clinical pharmacology and pharmacokinetics of oxcarbazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156973/),h,8-10,135672,DB01023,Felodipine
,3327676,elimination half-life,The mean elimination half-life of felodipine is approximately 25h.,Clinical pharmacokinetics of felodipine. A summary. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),h,25,140911,DB01023,Felodipine
,3327676,volume of distribution,"The volume of distribution of felodipine is about 10 L/kg, implying that less than 1% of the amount of drug in the body is localised in the blood.",Clinical pharmacokinetics of felodipine. A summary. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [kg],10,140912,DB01023,Felodipine
,3327676,total clearance from the blood,"Mean total clearance from the blood is 1 to 1.5 L/min and, therefore, felodipine is considered a high clearance drug.",Clinical pharmacokinetics of felodipine. A summary. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [min],1 to 1.5,140913,DB01023,Felodipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,94,142680,DB01023,Felodipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,89,142681,DB01023,Felodipine
,32139488,AUC0-8,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,14.4,147032,DB01023,Felodipine
,32139488,AUC0-8,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,17.6,147033,DB01023,Felodipine
,32139488,AUC0-8,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,25.7,147034,DB01023,Felodipine
,32139488,Cmax,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,3.5,147035,DB01023,Felodipine
,32139488,Cmax,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,4.0,147036,DB01023,Felodipine
,32139488,Cmax,"Groups A, B+C and D had linear trends of increasing felodipine AUC0-8; mean±SEM, 14.4±2.1, 17.6±2.8, 25.7±5.0; p<0.05) and Cmax (3.5±0.5, 4.0±0.6, 6.4±1.1; p<0.02), respectively.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,6.4,147037,DB01023,Felodipine
,32139488,AUC0 - 8,"Healthy subjects receiving water had lower felodipine AUC0 - 8 (11.9±0.9 vs 26.9±0.9, p=0.0001) and Cmax (2.9±0.2 vs 7.7±0.2, p=0.0001) relative to those receiving grapefruit juice.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,11.9,147038,DB01023,Felodipine
,32139488,AUC0 - 8,"Healthy subjects receiving water had lower felodipine AUC0 - 8 (11.9±0.9 vs 26.9±0.9, p=0.0001) and Cmax (2.9±0.2 vs 7.7±0.2, p=0.0001) relative to those receiving grapefruit juice.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,26.9,147039,DB01023,Felodipine
,32139488,Cmax,"Healthy subjects receiving water had lower felodipine AUC0 - 8 (11.9±0.9 vs 26.9±0.9, p=0.0001) and Cmax (2.9±0.2 vs 7.7±0.2, p=0.0001) relative to those receiving grapefruit juice.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,2.9,147040,DB01023,Felodipine
,32139488,Cmax,"Healthy subjects receiving water had lower felodipine AUC0 - 8 (11.9±0.9 vs 26.9±0.9, p=0.0001) and Cmax (2.9±0.2 vs 7.7±0.2, p=0.0001) relative to those receiving grapefruit juice.",Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32139488/),,7.7,147041,DB01023,Felodipine
,28189955,detection limits,Linear calibration ranges were obtained in the range 0.05-2.0μgmL-1 for FLD and MET and 0.1-2.0μgmL-1 for RAM with detection limits of 0.013-0.031μgmL-1 for all the studied drug combinations.,Ultrasound assisted dispersive liquid-liquid microextraction coupled with high performance liquid chromatography designated for bioavailability studies of felodipine combinations in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189955/),1/[μgml],0.013-0.031,147977,DB01023,Felodipine
,3593901,systemic availability,The systemic availability varied between 10 and 23 per cent.,"Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593901/),%,10 and 23,154125,DB01023,Felodipine
,12016918,recoveries,The plasma samples were extracted using a mixture of ethyl ether and n-hexane (2:1) to give mean recoveries of 97.3% of felodipine.,[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),%,97.3,155139,DB01023,Felodipine
,12016918,detection limits,The detection limits for felodipine was 0.25 ng.,[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),ng,0.25,155140,DB01023,Felodipine
,12016918,T1/2 alpha,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,0.76,155141,DB01023,Felodipine
,12016918,T1/2 beta,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,16.09,155142,DB01023,Felodipine
,12016918,Cmax,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),ng,4.78,155143,DB01023,Felodipine
,12016918,Tmax,"ml-1, Tmax = 2.01 h, AUC = 45.2 h.ng.ml-1.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,2.01,155144,DB01023,Felodipine
,12016918,AUC,"ml-1, Tmax = 2.01 h, AUC = 45.2 h.ng.ml-1.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),[h·ng] / [ml],45.2,155145,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB01023,Felodipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB01023,Felodipine
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,5.0,160632,DB01023,Felodipine
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,7.5,160633,DB01023,Felodipine
,32529303,oral bioavailability,"Felodipine (FLD), a dihydropyridine calcium channel blocker with excellent antihypertensive effect, is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),%,15,164432,DB01023,Felodipine
,32529303,zeta-potential,"The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (- 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),mv,- 25.53,164433,DB01023,Felodipine
,32529303,en,"The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (- 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),,95.65,164434,DB01023,Felodipine
,3443058,maximal felodipine plasma concentration,"At steady state, the maximal felodipine plasma concentration was 25.2 +/- 1.5 nmol/L and occurred 1.3 +/- 0.2 (range 1 to 3) hours after drug intake.",Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443058/),[nM] / [l],25.2,167674,DB01023,Felodipine
,3443058,maximal felodipine plasma concentration,"After 2 weeks' treatment, the maximal felodipine plasma concentration was 23.3 +/- 2.7 nmol/L and was reached 4.4 +/- 0.5 (range 3 to 7) hours after each dose.",Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443058/),[nM] / [l],23.3,167675,DB01023,Felodipine
,28971609,AUC0-8,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),[h·ng] / [ml],25,168680,DB01023,Felodipine
,28971609,AUC0-8,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),[h·ng] / [ml],13,168681,DB01023,Felodipine
,28971609,Cmax,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),[ng] / [ml],5.8,168682,DB01023,Felodipine
,28971609,Cmax,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),[ng] / [ml],2.7,168683,DB01023,Felodipine
,28971609,AUC0-8 ratio,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),,0.84,168684,DB01023,Felodipine
,28971609,AUC0-8 ratio,"Grapefruit increased felodipine AUC0-8 (25 vs. 13 ng.h/mL, P < 0.001) and Cmax (5.8 vs. 2.7 ng/mL, P < 0.001) and decreased dehydrofelodipine/felodipine AUC0-8 ratio (0.84 vs. 1.29, P < 0.001), while the three coffees caused no change in these parameters compared to water.",Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971609/),,1.29,168685,DB01023,Felodipine
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),[nM] / [l],0.25,170807,DB01023,Felodipine
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),μ,0.10,170808,DB01023,Felodipine
,3443063,Plasma half-life,"Plasma half-life in the 4- to 10-hour period of felodipine was 5.5 hours after a 10mg single dose, and 12 hours after 10mg bid.",Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443063/),h,5.5,171648,DB01023,Felodipine
,3443063,Plasma half-life,"Plasma half-life in the 4- to 10-hour period of felodipine was 5.5 hours after a 10mg single dose, and 12 hours after 10mg bid.",Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443063/),h,12,171649,DB01023,Felodipine
,3677507,systemic availability,"The systemic availability of felodipine after the acute dose was 15%, and at steady state 12% (N.S.), with a 3-fold variation between patients.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),%,15,172381,DB01023,Felodipine
,3677507,systemic availability,"The systemic availability of felodipine after the acute dose was 15%, and at steady state 12% (N.S.), with a 3-fold variation between patients.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),%,12,172382,DB01023,Felodipine
,3677507,plasma clearance,The mean plasma clearance was 0.6 L/h.,Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),[l] / [h],0.6,172383,DB01023,Felodipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.4,172384,DB01023,Felodipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.2,172385,DB01023,Felodipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.3,172386,DB01023,Felodipine
,3677507,terminal half-life,The mean terminal half-life was 24.5 h after the oral dose at steady state.,Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,24.5,172387,DB01023,Felodipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],26,173989,DB01023,Felodipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],7.5,173990,DB01023,Felodipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],4.3,173991,DB01023,Felodipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.80,173992,DB01023,Felodipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.83,173993,DB01023,Felodipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.84,173994,DB01023,Felodipine
,1992115,IC50,"The preparation of 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5- (methoxycarbonyl)-6-methyl-1,4-dihydropyridine (2) is described, and its potent calcium antagonist activity on rat aorta (IC50 = 4 x 10(-9) M) and marked tissue selectivity in vitro for vascular smooth muscle over cardiac smooth muscle are established.","Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),M,4 x 10(-9),174995,DB01023,Felodipine
,1992115,ED50,Compound 2 has excellent in vivo activity in the anesthetized dog (ED50 = 12 micrograms/kg for reduction of CVR) and a plasma half-life in the conscious dog of 7.2 h.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),[μg] / [kg],12,174996,DB01023,Felodipine
,1992115,plasma half-life,Compound 2 has excellent in vivo activity in the anesthetized dog (ED50 = 12 micrograms/kg for reduction of CVR) and a plasma half-life in the conscious dog of 7.2 h.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),h,7.2,174997,DB01023,Felodipine
,1992115,plasma clearance,The plasma clearance for 2 (9.6 mL/min/kg) is similar to that of amlodipine and is consistent with the extended 2-substituent hindering approach to the cytochrome P-450 enzyme responsible for oxidation of the DHP ring to the corresponding pyridine.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),[ml] / [kg·min],9.6,174998,DB01023,Felodipine
,17221914,constant mobile phase flow rate,A constant mobile phase flow rate of 1.0 mL/min was employed throughout the analyses.,Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221914/),[ml] / [min],1.0,186789,DB01023,Felodipine
,10220482,initial half-life,"The median initial half-life of the individual value (Bayesian estimates) is 12, 20, and 22 s in the rabbit, rat, and dog, respectively.","Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),s,12,190334,DB01023,Felodipine
,10220482,initial half-life,"The median initial half-life of the individual value (Bayesian estimates) is 12, 20, and 22 s in the rabbit, rat, and dog, respectively.","Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),s,20,190335,DB01023,Felodipine
,10220482,initial half-life,"The median initial half-life of the individual value (Bayesian estimates) is 12, 20, and 22 s in the rabbit, rat, and dog, respectively.","Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),s,22,190336,DB01023,Felodipine
,10220482,Emax,The mean maximum reduction in arterial blood pressure is 38 +/- 12% (Emax) and is achieved at 85 +/- 46 nM (EC50).,"Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),%,38,190337,DB01023,Felodipine
,10220482,EC50,The mean maximum reduction in arterial blood pressure is 38 +/- 12% (Emax) and is achieved at 85 +/- 46 nM (EC50).,"Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),nM,85,190338,DB01023,Felodipine
,10220482,half-life for reaching equilibrium,The half-life for reaching equilibrium between the central and the effect compartment (T1/2ke0) is 47 +/- 49 s.,"Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220482/),s,47,190339,DB01023,Felodipine
,12811362,area under the plasma concentration-time curve (AUC),"Grapefruit juice increased the mean felodipine area under the plasma concentration-time curve (AUC) (mean +/- SE, 55 +/- 9 nmol.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),nM,55,192683,DB01023,Felodipine
,12811362,plasma peak drug concentration,"h/L; P <.05) and the plasma peak drug concentration (16 +/- 3 nmol/L versus 8 +/- 2 nmol/L, P <.05) and decreased the dehydrofelodipine/felodipine AUC ratio compared with those of water.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),[nM] / [l],16,192684,DB01023,Felodipine
,12811362,plasma peak drug concentration,"h/L; P <.05) and the plasma peak drug concentration (16 +/- 3 nmol/L versus 8 +/- 2 nmol/L, P <.05) and decreased the dehydrofelodipine/felodipine AUC ratio compared with those of water.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),[nM] / [l],8,192685,DB01023,Felodipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB01023,Felodipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB01023,Felodipine
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"4,910",201527,DB01023,Felodipine
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"5,581",201528,DB01023,Felodipine
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],40,201529,DB01023,Felodipine
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],47,201530,DB01023,Felodipine
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),[mg] / [l],7.0,206263,DB01023,Felodipine
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),mg,7.4,206264,DB01023,Felodipine
,12803765,dissolution ratio,"Using a paddle speed combination of 75 and 125 rev min(-1) to represent the motility patterns in response to administration of normal saline and 5% glucose, respectively, the in-vitro ratios (75:125 rev min(-1) dissolution ratio was 91% for the micronised and 46% for the coarse-grade powder) showed good agreement with the pharmacokinetic data (saline-to-glucose absorption ratio was 98% for the micronised and 46% for the coarse-grade powder).",Can the USP paddle method be used to represent in-vivo hydrodynamics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803765/),%,91,207277,DB01023,Felodipine
,12803765,dissolution ratio,"Using a paddle speed combination of 75 and 125 rev min(-1) to represent the motility patterns in response to administration of normal saline and 5% glucose, respectively, the in-vitro ratios (75:125 rev min(-1) dissolution ratio was 91% for the micronised and 46% for the coarse-grade powder) showed good agreement with the pharmacokinetic data (saline-to-glucose absorption ratio was 98% for the micronised and 46% for the coarse-grade powder).",Can the USP paddle method be used to represent in-vivo hydrodynamics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803765/),%,46,207278,DB01023,Felodipine
,12803765,saline-to-glucose absorption ratio,"Using a paddle speed combination of 75 and 125 rev min(-1) to represent the motility patterns in response to administration of normal saline and 5% glucose, respectively, the in-vitro ratios (75:125 rev min(-1) dissolution ratio was 91% for the micronised and 46% for the coarse-grade powder) showed good agreement with the pharmacokinetic data (saline-to-glucose absorption ratio was 98% for the micronised and 46% for the coarse-grade powder).",Can the USP paddle method be used to represent in-vivo hydrodynamics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803765/),%,98,207279,DB01023,Felodipine
,12803765,saline-to-glucose absorption ratio,"Using a paddle speed combination of 75 and 125 rev min(-1) to represent the motility patterns in response to administration of normal saline and 5% glucose, respectively, the in-vitro ratios (75:125 rev min(-1) dissolution ratio was 91% for the micronised and 46% for the coarse-grade powder) showed good agreement with the pharmacokinetic data (saline-to-glucose absorption ratio was 98% for the micronised and 46% for the coarse-grade powder).",Can the USP paddle method be used to represent in-vivo hydrodynamics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803765/),%,46,207280,DB01023,Felodipine
,2612087,total peripheral resistance,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[mmhg] / [l·min],13,209446,DB01023,Felodipine
,2612087,total peripheral resistance,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[mmhg] / [l·min],17,209447,DB01023,Felodipine
,2612087,heart rate,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,72,209448,DB01023,Felodipine
,2612087,heart rate,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,67,209449,DB01023,Felodipine
,2612087,cardiac index,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[l] / [m2·min],3.7,209450,DB01023,Felodipine
,2612087,cardiac index,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[l] / [m2·min],3.0,209451,DB01023,Felodipine
,2612087,heart rate,"Co-administration of ethanol decreased standing systolic (113 +/- 8 vs 126 +/- 5 mmHg, p less than 0.01) and diastolic (69 +/- 5 vs 82 +/- 3 mmHg, p less than 0.01) blood pressure to a greater degree, but heart rate was not altered (87 +/- 6 vs 84 +/- 3 bpm).",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,87,209452,DB01023,Felodipine
,2612087,heart rate,"Co-administration of ethanol decreased standing systolic (113 +/- 8 vs 126 +/- 5 mmHg, p less than 0.01) and diastolic (69 +/- 5 vs 82 +/- 3 mmHg, p less than 0.01) blood pressure to a greater degree, but heart rate was not altered (87 +/- 6 vs 84 +/- 3 bpm).",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,84,209453,DB01023,Felodipine
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],173.25,213747,DB01023,Felodipine
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],275.61,213748,DB01023,Felodipine
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],223.26,213749,DB01023,Felodipine
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],561.32,213750,DB01023,Felodipine
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],2050.48,213751,DB01023,Felodipine
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],3650.22,213752,DB01023,Felodipine
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],3276.51,213753,DB01023,Felodipine
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],7265.25,213754,DB01023,Felodipine
,1577050,Cmax,"Compared to water, grapefruit juice caused an increase in Cmax from mean 6 to 16 nmol.l-1, and in the AUC from 23 to 65 nmol.",Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577050/),[nM] / [l],6 to 16,220091,DB01023,Felodipine
,1577050,AUC,"Compared to water, grapefruit juice caused an increase in Cmax from mean 6 to 16 nmol.l-1, and in the AUC from 23 to 65 nmol.",Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577050/),nM,23,220092,DB01023,Felodipine
,1577050,AUC,"Compared to water, grapefruit juice caused an increase in Cmax from mean 6 to 16 nmol.l-1, and in the AUC from 23 to 65 nmol.",Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577050/),nM,65,220093,DB01023,Felodipine
,29423833,oral bioavailability,"The oral bioavailability of felodipine (FEL) is very low, i.e., about 15%.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),%,15,234444,DB01023,Felodipine
,29423833,J,"The optimized buccal gel (MEF-PCP1) showed significantly higher (p < 0.01) permeation flux (J = 0.44 ± 0.16 mg/cm2/h), when compared with the drug suspension (J = 0.17 ± 0.14 mg/cm2/h).",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[mg] / [cm2·h],0.44,234445,DB01023,Felodipine
,29423833,J,"The optimized buccal gel (MEF-PCP1) showed significantly higher (p < 0.01) permeation flux (J = 0.44 ± 0.16 mg/cm2/h), when compared with the drug suspension (J = 0.17 ± 0.14 mg/cm2/h).",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[mg] / [cm2·h],0.17,234446,DB01023,Felodipine
,29423833,spreadability,"The texture profile analysis of MEF-PCP1 was performed which showed spreadability (3.2 mJ), extrudability (151.8 mJ), hardness (13.8 g), and adhesiveness (41.0 g), and results indicated good spreadability and adhesiveness.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),mj,3.2,234447,DB01023,Felodipine
,29423833,extrudability,"The texture profile analysis of MEF-PCP1 was performed which showed spreadability (3.2 mJ), extrudability (151.8 mJ), hardness (13.8 g), and adhesiveness (41.0 g), and results indicated good spreadability and adhesiveness.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),mj,151.8,234448,DB01023,Felodipine
,29423833,Cmax,The Cmax value 9.21 ± 2.88 μg/ml of MEF-PCP1 gel was found to be significantly higher (P < 0.01) compared to the same dose administered by oral route (Cmax value 3.51 ± 1.74 μg/ml).,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[μg] / [ml],9.21,234449,DB01023,Felodipine
,29423833,Cmax,The Cmax value 9.21 ± 2.88 μg/ml of MEF-PCP1 gel was found to be significantly higher (P < 0.01) compared to the same dose administered by oral route (Cmax value 3.51 ± 1.74 μg/ml).,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[μg] / [ml],3.51,234450,DB01023,Felodipine
,29423833,relative bioavailability (Fr),The relative bioavailability (Fr) of the optimized MEF-PCP1 buccal gel was about 397.39% higher than that of oral route.,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),%,397.39,234451,DB01023,Felodipine
,29204927,oral bioavailability,"The oral bioavailability of felodipine, a dihydropyridine calcium channel antagonist, is about 15%.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),%,15,234801,DB01023,Felodipine
,29204927,apparent permeability coefficients (Papp),"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],7.918 × 10-5,234802,DB01023,Felodipine
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],3.013,234803,DB01023,Felodipine
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],4.428,234804,DB01023,Felodipine
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],5.335 × 10-5,234805,DB01023,Felodipine
,29204927,C max,The optimized felodipine-loaded microemulsion showed significantly higher (p < 0.01) C max (7.12 ± 1.04 μg/ml) than marketed tablets (2.44 ± 1.03 μg/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[μg] / [ml],7.12,234806,DB01023,Felodipine
,29204927,C max,The optimized felodipine-loaded microemulsion showed significantly higher (p < 0.01) C max (7.12 ± 1.04 μg/ml) than marketed tablets (2.44 ± 1.03 μg/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[μg] / [ml],2.44,234807,DB01023,Felodipine
,29204927,AUClast,It was found that AUClast obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 μg h/ml) was significantly higher (p < 0.01) than the marketed tablet (27.41 ± 5.54 μg h/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[h·μg] / [ml],84.53,234808,DB01023,Felodipine
,29204927,AUClast,It was found that AUClast obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 μg h/ml) was significantly higher (p < 0.01) than the marketed tablet (27.41 ± 5.54 μg h/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[h·μg] / [ml],27.41,234809,DB01023,Felodipine
,29204927,relative bioavailability (Fr),The relative bioavailability (Fr) of the optimized felodipine-loaded microemulsion was about 308.3% higher than that of the marketed formulation.,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),%,308.3,234810,DB01023,Felodipine
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB01023,Felodipine
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB01023,Felodipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB01023,Felodipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB01023,Felodipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB01023,Felodipine
,9401833,peak-to-trough plasma concentration ratio,"After repeated dosing the peak-to-trough plasma concentration ratio were 1.58 and 4.43 (p < 0.001) for amlodipine and felodipine ER, respectively.",Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401833/),,1.58,240501,DB01023,Felodipine
,9401833,peak-to-trough plasma concentration ratio,"After repeated dosing the peak-to-trough plasma concentration ratio were 1.58 and 4.43 (p < 0.001) for amlodipine and felodipine ER, respectively.",Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401833/),,4.43,240502,DB01023,Felodipine
,19110105,flow rate,The effluent was monitored by UV detector at 240 nm and at a flow rate of 1.0 mL min(-1).,Development of high performance liquid chromatography method for lacidipine in rabbit serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19110105/),[ml] / [min],1.0,243382,DB01023,Felodipine
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],37,244832,DB01023,Felodipine
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],25,244833,DB01023,Felodipine
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],19,244834,DB01023,Felodipine
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],18,244835,DB01023,Felodipine
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],118,244836,DB01023,Felodipine
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],84,244837,DB01023,Felodipine
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],64,244838,DB01023,Felodipine
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],59,244839,DB01023,Felodipine
,2442513,elimination half-life,Determination of the plasma concentrations of felodipine during steady-state conditions showed a mean elimination half-life of 23.4 +/- 11.1 h.,Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442513/),h,23.4,251896,DB01023,Felodipine
,1691367,absolute bioavailability,The absolute bioavailability of felodipine ER was 22%.,Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1691367/),%,22,251912,DB01023,Felodipine
,28424979,overall absorption,The simulated regional absorption of the FLN presented significant absorption from the cecum (26.3%) and ascending colon (20.1%) with overall absorption of 67.4% from the GIT tract.,Studies on Core-Shell Nanocapsules of Felodipine: In Vitro-In Vivo Evaluations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28424979/),%,67.4,253792,DB01023,Felodipine
,15592332,C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),[ng] / [ml],2.1,257055,DB01023,Felodipine
,15592332,C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),[ng] / [ml],5.9,257056,DB01023,Felodipine
,15592332,times to reach C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),h,0.8,257057,DB01023,Felodipine
,15592332,times to reach C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),h,1.1,257058,DB01023,Felodipine
,1343111,Emax,The average Emax value was estimated to be approximately 30 mmHg.,Felodipine pharmacokinetics and plasma concentration vs effect relationships. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1343111/),mmhg,30,259406,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[h·nM] / [l],81,260289,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],20,260290,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[h·nM] / [l],117,260291,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[h·nM] / [l],130,260292,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],33,260293,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[h·nM] / [l],53,260294,DB01023,Felodipine
,9757148,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],11,260295,DB01023,Felodipine
,9757148,peak concentration (Cmax),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],20,260296,DB01023,Felodipine
,9757148,peak concentration (Cmax),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],33,260297,DB01023,Felodipine
,9757148,peak concentration (Cmax),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[h·nM] / [l],53,260298,DB01023,Felodipine
,9757148,peak concentration (Cmax),"The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of felodipine were higher with supernatant fraction (81 nmol.h/L and 20 nmol/L), particulate fraction (117 nmol.h/L and 24 nmol/L), and grapefruit juice (130 nmol.h/L and 33 nmol/L) compared with water (53 nmol.h/L and 11 nmol/L).","Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757148/),[nM] / [l],11,260299,DB01023,Felodipine
,26478413,oral relative bioavailability,"Pharmacokinetic results indicated that the oral relative bioavailability of self-made FDP-3DOMTS tablets were 184%, showing that 3DOMTS produced a significantly increased oral absorption of FDP.",Development of a novel starch with a three-dimensional ordered macroporous structure for improving the dissolution rate of felodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26478413/),%,184,261772,DB01023,Felodipine
,8321836,Gastric emptying,"Gastric emptying after administration together with food (mean, 3.2 hr) was slower in all subjects compared to emptying under fasting conditions (mean, 0.6 hr).","Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321836/),h,3.2,262852,DB01023,Felodipine
,8321836,Gastric emptying,"Gastric emptying after administration together with food (mean, 3.2 hr) was slower in all subjects compared to emptying under fasting conditions (mean, 0.6 hr).","Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321836/),h,0.6,262853,DB01023,Felodipine
,8321836,small intestinal transit times,"The mean small intestinal transit times for the two study conditions did not differ significantly (5.1 and 4.7 hr, respectively).","Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321836/),h,5.1,262854,DB01023,Felodipine
,8321836,small intestinal transit times,"The mean small intestinal transit times for the two study conditions did not differ significantly (5.1 and 4.7 hr, respectively).","Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321836/),h,4.7,262855,DB01023,Felodipine
,4017422,time to peak concentration,"Given as an oral solution, felodipine is rapidly (mean time to peak concentration 64 minutes; range 30 to 90 minutes) and completely absorbed.",Felodipine kinetics in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),min,64,264399,DB01023,Felodipine
,4017422,t1/2,"The t1/2 for the initial phase was 6.4 minutes (range 1.7 to 10.4 minutes) and felodipine was distributed to a volume of 0.6 L/kg (range 0.4 to 0.9 L/kg), which approximately corresponds to the total body water.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),min,6.4,264400,DB01023,Felodipine
,4017422,volume,"The t1/2 for the initial phase was 6.4 minutes (range 1.7 to 10.4 minutes) and felodipine was distributed to a volume of 0.6 L/kg (range 0.4 to 0.9 L/kg), which approximately corresponds to the total body water.",Felodipine kinetics in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [kg],0.6,264401,DB01023,Felodipine
,4017422,t1/2,The second distribution phase reached pseudoequilibrium with a t1/2 of 1.6 hours (range 1.3 to 2.2 hours).,Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,1.6,264402,DB01023,Felodipine
,4017422,volume of distribution,The volume of distribution at the end of this phase was 9.7 L/kg (range 6.0 to 18.2 L/kg).,Felodipine kinetics in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [kg],9.7,264403,DB01023,Felodipine
,4017422,terminal,The terminal phase had t1/2 of 10.2 hours (range 6.7 to 20.7 hours).,Felodipine kinetics in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,10.2,264404,DB01023,Felodipine
,4017422,t1/2,The terminal phase had t1/2 of 10.2 hours (range 6.7 to 20.7 hours).,Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,10.2,264405,DB01023,Felodipine
,4017422,Total body clearance,Total body clearance of felodipine was 1.2 L/min (range 0.9 to 1.6 L/min).,Felodipine kinetics in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [min],1.2,264406,DB01023,Felodipine
,4017422,t1/2,"The rate of excretion by the kidneys had a biphasic pattern, with t1/2 values of 4 and 18 hours.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,4,264407,DB01023,Felodipine
,4017422,t1/2,"The rate of excretion by the kidneys had a biphasic pattern, with t1/2 values of 4 and 18 hours.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,18,264408,DB01023,Felodipine
,2900404,oral bioavailability,"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,15,266162,DB01023,Felodipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],1.6,266163,DB01023,Felodipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],8.9,266164,DB01023,Felodipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],2.0,266165,DB01023,Felodipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],30.0,266166,DB01023,Felodipine
,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,6.6,266167,DB01023,Felodipine
less,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,1,266168,DB01023,Felodipine
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,13,269502,DB01023,Felodipine
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,12.5,269503,DB01023,Felodipine
,2243149,terminal plasma half-life (t1/2),The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),h,22,269504,DB01023,Felodipine
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],490,269505,DB01023,Felodipine
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],434,269506,DB01023,Felodipine
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.74,269507,DB01023,Felodipine
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.73,269508,DB01023,Felodipine
,2753065,Cmax,"The mean peak plasma concentration normalized to a dose of 10 mg (Cmax 46 nmol/l) was twice as high in the cirrhotic patients as in the healthy subjects, but the bioavailability, f, (17.0%) was comparable.",Pharmacokinetics of felodipine in patients with liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753065/),[nM] / [l],46,271281,DB01023,Felodipine
,2753065,"bioavailability, f","The mean peak plasma concentration normalized to a dose of 10 mg (Cmax 46 nmol/l) was twice as high in the cirrhotic patients as in the healthy subjects, but the bioavailability, f, (17.0%) was comparable.",Pharmacokinetics of felodipine in patients with liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753065/),%,17.0,271282,DB01023,Felodipine
